New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
16:29 EDTAMRNOn The Fly: Top stock stories for Thursday
Subscribe for More Information
14:31 EDTAMRNAmarin granted summary judgment motion in suit against FDA over Vascepa
Subscribe for More Information
13:36 EDTAMRNAmarin surges after court sides with company on Vascepa exclusivity
Shares of Amarin Pharmaceuticals are surging higher after a U.S. district court sided with the company in its challenge of the Food and Drug Administrationís determination that Amarinís new drug, Vascepa, is not entitled to a five-year period of market exclusivity under the Federal Food, Drug, and Cosmetic Act. The court granted the company's motion for summary judgment and the decision denying Amarinís claim for exclusivity was vacated. The matter was remanded to the FDA for proceedings consistent with the court's opinion. In afternoon trading, Amarin shares jumped as high as $2.80 and are now up 22.5% to $2.39.
13:29 EDTAMRNAmarin wins district court ruling on Vascepa exclusivity
Amarin shares jumped 31% following the ruling.
May 26, 2015
08:14 EDTGSKBoston Biotech Conferences to hold a conference
Subscribe for More Information
May 22, 2015
10:52 EDTGSKJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
10:32 EDTAMRNAmarin management to meet with Oppenheimer
Meeting to be held in New York on May 27 hosted by Oppenheimer.
May 21, 2015
07:37 EDTGSKPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
07:46 EDTGSKDeutsche Bank positive on potential Pfizer, GSK merger
Deutsche Bank analyst Gregg Gilbert believes a large foreign deal for Pfizer (PFE) may make sense and says a buyout of GlaxoSmithKline (GSK) could be "materially" accretive to earnings while improving the company's tax situation over time. Gilbert assumes a $60 per share buyout price for GlaxoSmithKline in a research note this morning titled "Introducing 'PfizerKline'". The stock closed yesterday up 2c to $44.68. Gilbert reiterates a Buy rating on Pfizer with a $41 price target. Shares ended yesterday up 23c to $34.21.
May 19, 2015
09:25 EDTGSKGlaxoSmithKline asthma drug overused, risks underappreciated, ProPublica says
Subscribe for More Information
06:55 EDTGSKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 15, 2015
15:11 EDTGSKGlaxoSmithKline reports 16.12% stake in HTG Molecular
Subscribe for More Information
09:31 EDTGSKAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use